Dr. Sereti on novel agent NOV202 plus olaparib in prostate cancer

Evangelia Sereti, MSc, PhD, discusses the design/methodology and results of a preclinical study exploring the combination of the PARP inhibitor olaparib plus the novel agent NOV202 in BRCA1/2-mutated prostate cancer cells.

Read the full article here

Related Articles